Lantern Pharma (LTRN) Capital Expenditures (2021 - 2025)

Lantern Pharma (LTRN) has reported Capital Expenditures for 5 consecutive years, with $1.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures fell 99.97% year-over-year to $1.0; the trailing twelve-month figure through Dec 2025 stood at $1715.0 (down 86.38% YoY), and the FY2025 full-year result was $1715.0, down 86.38% from the prior year.
• Capital Expenditures fell to $1.0 in Q4 2025 per LTRN's latest filing, from $555.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $8876.0 in Q1 2023 and bottomed at $1.0 in Q4 2021.
• Historically, Capital Expenditures has averaged $3585.4 across 5 years, with a median of $3283.5 in 2021.
• The sharpest annual moves came in 2022 and 2025: Capital Expenditures surged 695400.0% in 2022, then plunged 99.97% in 2025.
• Over 5 years, Capital Expenditures stood at $1.0 in 2021, then soared by 695400.0% to $6955.0 in 2022, then retreated by 26.94% to $5081.0 in 2023, then sank by 39.32% to $3083.0 in 2024, then slumped by 99.97% to $1.0 in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered $1.0, $555.0, and $1159.0 for Q4 2025, Q3 2025, and Q1 2025 respectively.